DOES ADJUVANT CHEMOTHERAPY BENEFIT HIGH-RISK STAGE 2 COLON CANCER: A NOMOGRAM TO PREDICT REDUCTION IN 5-YEAR MORTALITY RISK WITH ADJUVANT CHEMOTHERAPY.

被引：0
|
作者：
Graham, A. E.
Sparks, A.
Umapathi, B.
机构：
来源：
DISEASES OF THE COLON & RECTUM | 2019年 / 62卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P36
引用
收藏
页码：E121 / E122
页数：2
相关论文
共 50 条
  • [21] DEVELOPMENT OF A NOMOGRAM TO PREDICT INDIVIDUAL BENEFIT ATTAINED FROM ADDITION OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF STAGE II COLON CANCER
    Merritt, Clay M.
    Chang, Shu-Ching
    Grunkemeier, Gary L.
    Steele, Scott
    Goldfarb, Melanie
    Nelson, Daniel
    GASTROENTEROLOGY, 2020, 158 (06) : S1545 - S1545
  • [22] Impact of Adjuvant Chemotherapy on Recurrence Risk in Stage II Colon Cancer
    Adesoye, T.
    Hu, C.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S91 - S91
  • [23] High-risk endometrial cancer may be benefit from adjuvant radiotherapy plus chemotherapy
    Miao, Jin-Wei
    Deng, Xiao-Hong
    CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (04) : 332 - 339
  • [24] High-risk endometrial cancer may be benefit from adjuvant radiotherapy plus chemotherapy
    Jin-Wei Miao
    Xiao-Hong Deng
    Chinese Journal of Cancer Research, 2012, 24 (04) : 332 - 339
  • [25] Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
    Hu, Huabin
    Wu, Zehua
    Wang, Chao
    Huang, Yan
    Zhang, Jianwei
    Cai, Yue
    Xie, Xiaoyu
    Li, Jianxia
    Shen, Cailu
    Li, Weiwei
    Ling, Jiayu
    Xu, Xuehu
    Deng, Yanhong
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [26] Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa
    Tan, Sarah Xinhui
    Pumpalova, Yoanna
    Rogers, Alexandra M. M.
    Bhatt, Kishan
    Herbst, Candice-lee
    Ruff, Paul
    Neugut, Alfred I. I.
    Hur, Chin
    CANCER MEDICINE, 2023, 12 (14): : 15515 - 15529
  • [27] Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
    O'Connell, MJ
    Laurie, JA
    Kahn, M
    Fitzgibbons, RJ
    Erlichman, C
    Shepherd, L
    Moertel, CG
    Kocha, WI
    Pazdur, R
    Wieand, HS
    Rubin, J
    Vukov, AM
    Donohue, JH
    Krook, JE
    Figueredo, A
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 295 - 300
  • [28] Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer
    McCaw, Zachary R.
    Kim, Dae Hyun
    Wei, Lee-Jen
    JAMA ONCOLOGY, 2020, 6 (08) : 1301 - +
  • [29] The number of cycles of adjuvant chemotherapy in stage III and high-risk stage II rectal cancer: a nomogram and recursive partitioning analysis
    Chen, Wei-Wei
    Wang, Wen-Ling
    Dong, Hong-Min
    Wang, Gang
    Li, Xiao-Kai
    Li, Guo-Dong
    Chen, Wang-Hua
    Chen, Juan
    Bai, Sai-Xi
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [30] The number of cycles of adjuvant chemotherapy in stage III and high-risk stage II rectal cancer: a nomogram and recursive partitioning analysis
    Wei-Wei Chen
    Wen-Ling Wang
    Hong-Min Dong
    Gang Wang
    Xiao-Kai Li
    Guo-Dong Li
    Wang-Hua Chen
    Juan Chen
    Sai-Xi Bai
    World Journal of Surgical Oncology, 20
12345